Related Experiment Video
Updated: May 11, 2026

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
[Familial Mediterranean fever: not to be missed]
Joost Frenkel1, Frederike J Bemelman, Bert-Jan Potter van Loon
1Universitair Medisch Centrum Utrecht, afd. Algemene Pediatrie, Utrecht, the Netherlands. j.frenkel@umcutrecht.nl
Abstract:
Familial Mediterranean fever (FMF) is common among Turkish and Moroccan migrants. We describe three patients with FMF. A 3-year-old girl with recurrent fever and abdominal pain who was diagnosed early with FMF and treated effectively with colchicine. An adolescent girl who required interleukin (IL)-1 blockade to achieve disease remission. And a 37-year-old woman in whom the attacks of FMF had not been recognised, but who developed end-stage kidney failure due to AA amyloidosis. Mutations in the MEFV gene underlie the disease in most but not all patients. Therefore, FMF remains a clinical diagnosis. FMF patients suffer recurrent bouts of inflammation, often with fever, serositis or arthritis. The major complication is AA amyloidosis. The inflammatory process is mediated by IL-1β. When started early, colchicine prophylaxis can prevent amyloidosis. When colchicine fails, IL-1 blockade has shown promising results. Timely diagnosis and treatment can make the difference between near normal health and end-stage kidney failure.
Insights
Familial Mediterranean fever (FMF) is a genetic inflammatory disease. Early diagnosis and treatment with colchicine or IL-1 blockade are crucial to prevent severe complications like kidney failure from AA amyloidosis.
Area of Science:
- Genetics
- Rheumatology
- Nephrology
Background:
- Familial Mediterranean fever (FMF) is a common autoinflammatory disorder, particularly prevalent in specific ethnic groups.
- FMF is characterized by recurrent episodes of fever, serositis, and arthritis, often leading to AA amyloidosis.
- Genetic mutations in the MEFV gene are associated with FMF, but diagnosis remains primarily clinical.
Observation:
- The study presents three cases of FMF in patients of varying ages.
- One patient achieved remission with colchicine, another required interleukin (IL)-1 blockade, and a third developed end-stage kidney failure due to unrecognized FMF and subsequent AA amyloidosis.
- These cases highlight the diverse clinical presentations and potential severity of FMF.
Findings:
- Early and appropriate treatment is critical for managing FMF and preventing its major complication, AA amyloidosis.
- Colchicine is effective for prophylaxis when initiated early.
- Interleukin (IL)-1 blockade offers a promising therapeutic option for patients unresponsive to colchicine.
Implications:
- Timely diagnosis and intervention in FMF can significantly alter patient outcomes, preventing debilitating conditions such as end-stage kidney failure.
- Understanding the inflammatory pathways, particularly IL-1β, is key to developing effective FMF treatments.
- Raising awareness of FMF among clinicians is essential for early recognition, especially in at-risk populations.
Related Concept Videos
Patterns of Fever
Types of Fever
Here are the different types of fever:
Myocarditis II: Clinical Features and Diagnostic Tests
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Encephalitis l: Introduction
Myocarditis I: Introduction
